RPRX · NASDAQ · STOCK
Royalty Pharma plc
$57.79
52W $34.08 – $60.44
56/100
$25.62B
24.0
0.42
Is RPRX Bullish or Bearish?
Mixed.
Innellis AI committee rates Royalty Pharma plc (RPRX) Watch with a composite score of 56/100
, based on 5 analysts with 60% agreement.
Last updated August 11, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +4.03 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -15.97 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Value Analyst remains cautious — p/e of 40.9 is expensive by classic value standards. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- P/E of 40.9 is expensive by classic value standards — Value
- EPS declining -15.9% YoY despite any revenue growth — Growth
- MACD histogram negative -- bearish momentum — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of August 11, 2026
Overall Committee Score
56/100
Agreement
60%
Analysts
5
Conviction
Contested
Sector Rank
Top 75%
of 192 Healthcare peers
Value Analyst
bearish
38
/ 100 · Moderate confidence
Multiples don't clear a genuine value bar here, or cheapness looks justified by weak fundamentals
− P/E of 40.9 is expensive by classic value standards
Growth Analyst
neutral
42
/ 100 · Moderate confidence
Moderate growth -- present but not remarkable
− EPS declining -15.9% YoY despite any revenue growth
Technical Analyst
bullish
61
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
− MACD histogram negative -- bearish momentum
Macro Analyst
bullish
78
/ 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst
bullish
61
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
Portfolio Manager
neutral
55
/ 100 · Moderate confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− 2 existing position pair(s) are highly correlated already
Technical Analysis
RSI (14)
49.6
Neutral
MACD Histogram
-0.244
Bearish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Hh Hl
Bollinger %B
0.41
Inside Bands
Price vs Moving Averages
EMA 9
$57.77
Above
EMA 21
$57.70
Above
EMA 50
$56.32
Above
EMA 200
$48.75
Above
Fundamental Analysis
Valuation
43
Profitability
75
Financial Health
50
Cash Flow
70
Valuation
P/E Ratio
24.0×
P/B Ratio
3.76×
PEG Ratio
6.98
Dividend Yield
1.57%
52W High
$60.44
52W Low
$34.08
Quality & Growth
ROE
1190.3%
ROA
392.9%
Gross Margin
8937.8%
Operating Margin
6234.3%
Revenue Growth YoY
—
Debt / Equity
1.31
AI Fundamental Assessment
[reduced confidence: limited earnings history] P/E ratio of 24.0 (inexpensive relative to a 15-40x range); Price-to-book of 3.8x; PEG ratio of 7.0 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 11.9%; Return on assets of 3.9%; Net margin of 32.1%; Gross margin of 89.4%; Current ratio of 1.29 (tight short-term liquidity); Debt-to-equity of 1.31; Free cash flow per share is positive (6.69); Earnings-history trend unavailable; growth based on TTM year-over-year only.
Get the Full RPRX Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →